

Document:	Industry standard	
Title:	CBD isolate	
Page:	1 of 5	
Version:	1	
Date:	11 November 2020	

1. Purpose

The purpose of this industry standard is to establish a quality standard for CBD isolate as a raw material for the food/supplements and cosmetics industry.

2. Definition

CBD stands for cannabidiol. CBD isolate is (pure) CBD of natural origin. CBD isolate is extracted from the above-ground parts of the hemp plant (flower and/or leaf), originating from (industrial) hemp species that contain less than 0.3% THC¹, including: EU permitted hemp species², Canadian permitted hemp species³, or USA permitted hemp species⁴. The production method should be suitable for use in food⁵.

3. Regulatory status

a. Dutch “Opium Act”

Although cannabidiol is not included in the schedules of the Opium Act, the production of CBD isolate in the Netherlands falls under the Opium Act and is illegal according to the Act:

- CBD isolate may contain traces of THC (Opiumwet schedule 1);
- The definition of cannabis applies to industrial hemp. It is not permitted to cultivate, extract, prepare, etc. cannabis (Opiumwet art 3);
- Only fibre and seed may be gained from industrial hemp (Opiumwetbesluit art 12).

Nevertheless, CBD isolate is condoned in the Netherlands in herbal products/food supplements under the Opium Act, if it complies to the following prerequisites:

- CBD isolate is manufactured from permitted industrial hemp species.
- The final product does not contain more than 0.05% (w/w) THC⁶.

b. Novel Food Regulation

As long as CBD isolate is covered by the Opium Act, the Novel Food Regulation⁷ does not apply.

Synthetically obtained cannabinoids are per definition considered Novel⁸ and prohibited for use in food and food supplements, unless a Novel Food authorization has been granted.

¹ https://www.europarl.europa.eu/doceo/document/TA-9-2020-0289_EN.html

² http://ec.europa.eu/food/plant/plant_propagation_material/plant_variety_catalogues_databases/search/ (choose: Agricultural plant species, and subsequently at species: A-85)

³ <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/producing-selling-hemp/commercial-licence/list-approved-cultivars-cannabis-sativa.html>

⁴ <https://www.federalregister.gov/documents/2019/10/31/2019-23749/establishment-of-a-domestic-hemp-production-program>

⁵ <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32009L0032>

⁶ besluit-wob-verzoek-over-over-de-stof-cannabidiol-cbd, 2018 (<https://rijksoverheid.archiefweb.eu/#archive> search: cannabidiol)

⁷ https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1449760581954&uri=OJ%3AJOL_2015_327_R_0001

⁸ http://ec.europa.eu/food/safety/novel_food/catalogue/search/public/index.cfm# search: Cannabis sativa L., Cannabidiol, Cannabinoids

Document:	Industry standard	
Title:	CBD isolate	
Page:	2 of 5	
Version:	1	
Date:	11 November 2020	

c. Cosmetics Regulation

CBD isolate is subject to the provisions of Annex II/306⁹ if extracted from the flowering parts of the hemp plant. If extracted from the leaves and free of THC, it is permitted for use in cosmetics¹⁰, as well as CBD of synthetic origin¹¹.

4. Maximum daily dose

The maximum recommended daily dose = 160 mg CBD¹². It is also possible to recommend a lower maximum dose.

Each label should contain the maximum recommended daily dosage, stated as the number of drops, capsules, etc.

5. Claims

No medical claims and no health claims are permitted. Not on the primary or secondary packaging, nor on any marketing material, including flyers, leaflets, ads, websites, blogs, etc.

Health claims are only permitted for ingredients that have been submitted to and approved by EFSA¹³. Until now, no claims have been submitted for CBD or hemp extracts.

In case an approved health claim is used, proof of the concentration/quantity of the relevant ingredient in the final product must be provided with the application for the quality mark.

6. Labelling requirements

The labelling requirements for CBD oil and CBD capsules are included in the relevant industry standards¹⁴.

⁹ <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32009R1223>

¹⁰ https://ec.europa.eu/growth/tools-databases/cosing/index.cfm?fuseaction=search.details_v2&id=97599

¹¹ https://ec.europa.eu/growth/tools-databases/cosing/index.cfm?fuseaction=search.details_v2&id=93486

¹² besluit-wob-verzoek-over-over-de-stof-cannabidiol-cbd, 2018 (<https://rijksoverheid.archiefweb.eu/#archive> search: cannabidiol)

¹³ http://ec.europa.eu/food/safety/labelling_nutrition/claims/register/public/?event=register.home

¹⁴ <https://www.cannabinoïdenadviesbureau.nl/en/diensten/keurmerk/>

Document:	Industry standard	
Title:	CBD isolate	
Page:	3 of 5	
Version:	1	
Date:	11 November 2020	

7. Test procedures¹⁵

#	Parameter	Specification	Preferred method
1	Appearance	White to light yellow crystalline powder	Visual
2	Scent	Odourless to light terpenic odour	Sensory
3	Melting point	63 – 69 °C	Melting point apparatus
4	Specific rotation	-130,0 ~ -140,0 °	Polarimeter
5	Total ash content	Max 0,3%	Ph Eur 2.4.16
6	Water content	Max. 1%	Karl Fisher
7	Heavy metals ¹⁶		
	Lead	Max. 3,0 mg/kg	Regulation (EC) 333/2007
	Cadmium	Max. 1,0 mg/kg	
	Mercury	Max. 0,1 mg/kg	
8	Pesticides	Acc to Regulation (EC) 396/2005	SANTE/11945/2015
9	Microbiology ¹⁷		
	TAMC	Max. 10 ⁴ CFU/ml	ISO 4833-1
	TYMC	Max. 10 ² CFU/ml	
	Enterobacteria	Max. 10 ² CFU/ml	
	Salmonella	Absent in 10 ml	
	E. coli	Absent in 1 ml	
S. aureus	Absent in 1 ml		
10	Residual solvents	Acc to Ph Eur 5.4	Ph Eur 2.4.24
11	Content CBD	97,5 – 102,5%	in-house method
12	Content THC	Max. 0,05% (w/w)	in-house method
13	Fingerprint cannabinoid profile (chromatogram)	Acc to company standard	in-house method

¹⁵ See Annex 1.1 for list of approved laboratories

¹⁶ Specifications are based on EU 1881/2006 dd. 01-01-2016 as laid down in the Annex (3.2.21, 3.1.22, 3.3.3)

¹⁷ Specifications are based on Ph Eur 5.1.4

Document:	Industry standard	
Title:	CBD isolate	
Page:	4 of 5	
Version:	1	
Date:	11 November 2020	

Annex 1 – list of laboratories

1. The appointed laboratories for tests 10 till 13 are:

- [BrightLabs](#)¹⁸
St. Jansweg 20
5928 RC Venlo
Netherlands

BrightLabs can perform all tests.

CAN members receive a 25% discount on the tests at BrightLabs. The reporting lead-time is 7 working days after receipt of the samples. The discount is not applicable in case of a lead-time of 5 working days. An additional discount is applicable if all tests are performed by Brightlabs.

- [Eurofins PROXY Laboratories](#)¹⁸
Archimedesweg 25
2333 CM Leiden
Netherlands

Proxylab can perform all tests.

The reporting lead-time is 10 working days after receipt of the samples.

- [ÖHMI Analytik GmbH](#)
Berliner Chaussee 66
39114 Magdeburg
Germany

Öhmi can also perform all tests.

The reporting lead-time is 7 working days after receipt of the samples. For a lead-time of 24 hours a surcharge of 100% is calculated and for 48 hours there is a surcharge of 50%.

- [Dept of Food Analysis and Nutrition \(UAPV\), UCT Prague](#)
Technická 3
16628 Praha 6
Czech Republic

CAN does not (yet) have any agreements with UAPV about analyses, prices and lead times.

¹⁸ No “Opiumontheffing” is required of the client if the sample contains less than 0,05% (w/w) THC. Samples that contain more than 0,05% (w/w) THC are reported with IGJ.

Document:	Industry standard	The logo for Cannabinoïden Adviesbureau Nederland (CAN) features the text "Cannabinoïden Adviesbureau Nederland" in a purple sans-serif font, with "CAN" in a larger, stylized purple font to the right. A horizontal purple line is positioned above the text.
Title:	CBD isolate	
Page:	5 of 5	
Version:	1	
Date:	11 November 2020	

2. The other tests (1 till 9) may for example also be performed by any of the following laboratories. These laboratories do not perform the assays on cannabinoids and only and only test if the assays have already been performed and the sample does not contain more than 0,05% THC!

- [NutriControl](#)
N.C.B. laan 52
5462 GE Veghel
Netherlands
- [NofaLab](#)
Jan van Galenstraat 41/51
3115 JG Schiedam
Netherlands